Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Investors - Lead Plaintiff Deadline on July 14, 2025
07:15am, Monday, 26'th May 2025
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal sec
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance
Levi & Korsinsky Urges Iovance (IOVA) Shareholders to Act Before Lead Plaintiff Deadline July 14, 2025
01:45pm, Sunday, 25'th May 2025
NEW YORK, NY / ACCESS Newswire / May 25, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal sec
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Before July 14, 2025 to Join Class Action
09:00am, Sunday, 25'th May 2025
NEW YORK, NY / ACCESS Newswire / May 25, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal sec
Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
07:47am, Sunday, 25'th May 2025
NEW YORK, NY / ACCESS Newswire / May 25, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal sec
NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certa
Levi & Korsinsky Urges Iovance (IOVA) Shareholders to Act Before Lead Plaintiff Deadline July 14, 2025
07:13am, Sunday, 25'th May 2025
NEW YORK, NY / ACCESS Newswire / May 25, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal sec
NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors - Contact Levi & Korsinsky Before July 14, 2025
06:01pm, Saturday, 24'th May 2025
NEW YORK, NY / ACCESS Newswire / May 24, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal sec
NEW YORK, May 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Iovance Biot
NEW YORK, NY / ACCESS Newswire / May 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Suc
NEW YORK and NEW ORLEANS , May 23, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in exce
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Over Securities Violations - Contact Levi & Korsinsky Today
06:00pm, Friday, 23'rd May 2025
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal sec
SAN DIEGO, CA / ACCESS Newswire / May 23, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Iovance Bioth
Class Action Alert: Levi & Korsinsky Reminds Iovance (IOVA) Investors of July 14, 2025 Deadline
05:30pm, Friday, 23'rd May 2025
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal sec
